期刊文献+

骨保护素基因rs2073617T/C、rs2073618G/C多态性在东南沿海地区汉族人群中分布及与急性冠状动脉综合征相关性研究 被引量:2

Correlation between osteoprotegerin gene rs2073617T/C,rs2073618G/C polymorphism and acute coronary syndromes in Fujian area
原文传递
导出
摘要 目的探讨骨保护素(OPG)基因启动子rs2073617T/C和第一外显子rs2073618G/C位点基因多态性在福建地区汉族人群中的分布及与急性冠状动脉综合征(ACS)的相关性。方法纳入720例福建地区无血缘关系的汉族人为研究对象,分成ACS360例(ACS组)和对照组360例(对照组),采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对OPG基因rs2073617T/C和rs2073618G/C多态性位点进行基因型分型,同时采用DNA测序对酶切产物进行鉴定。结果 (1)在福建地区汉族人群中,OPG基因rs2073617T/C多态性位点存在TC、TT、CC三种基因型;rs2073618G/C多态性位点也存在GG、GC、CC三种基因型。(2)对ACS组与正常对照组OPG基因rs2073617T/C、rs2073618G/C基因型及等位基因频率分布进行比较均无统计学差异(P均>0.05)。(3)ACS组患者单支病变、双支病变及三支以上病变组之间比较OPG基因rs2073617T/C、rs2073618G/C各基因型差异无统计学意义(P均>0.05)。结论福建地区汉族人群OPGrs2073617T/C、rs2073618G/C位点基因多态性与ACS发生无明确相关性。 Objective To study the genotype distribution of osteoprotegerin gene rs2073617T/C and rs2073618G/C polymorphism in Han population in Fujian area and discuss its association with acute coronary syndrome. Methods A total of seven hundreds and twenty consecutive patients with ACS of unrelated Fujian Han people was enrolled in the present study, three hundred and sixty patients with ACS ( case group) and 360 matched controls. OPG gene rs2073617T/C and rs2073618G/C were genotyped in all the patients enrolled using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). DNA sequences of enzyme digested products were also analyzed. Results ( 1 ) OPG rs2073617T/C polymorphism was existing in Hans population of Fujian, TC, TT,CC genotype. OPG rs2073618G/C polymorphism was existing in Hans population of Fujian, GG, GC, CC genotype. (2) No significant differences were observed in the genotype and allelic frequencies of OPG geue rs2073617T/C,rs2073618G/C between the ACS and control groups. (3)ACS patients with single vessel disease, double vessel disease and three or more lesions, OPG gene rs2073617T/C, rs2073618G/C in all lesions had no difference anmoy the groups. Conclusions OPG gene rs2073617T/C, rs2073618G/C polymorphism were not assoiated with acute coronary syndrome in Hans population of Fujian.
作者 罗助荣
出处 《中华临床医师杂志(电子版)》 2012年第15期25-28,共4页 Chinese Journal of Clinicians(Electronic Edition)
基金 军队医学科技创新项目资助(09MA094)
关键词 急性冠状动脉综合征 骨保护素 多态性 限制性片段长度 Acute coronary syndrome Osteoprotegerin Polymorphism,restriction fragment length
  • 相关文献

参考文献2

二级参考文献33

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2155

同被引文献39

  • 1Simonet WS,Lacey DL,Dunstall CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(2):309.
  • 2Vidal C,Formosa R,Xuereb-Anastasi A.Functional polymorphisms within the TNFRSF11B(osteoprotegerin)gene increase the risk for low bone mineral density[J].Journal of Molecular Endocrinology,2011,47(3):327-333.
  • 3郏蓉,纪立农.老年人BMD与OPG基因启动子区SNPs及骨代谢生化指标的相关分析研究[D].2011年北京医学会内分泌暨糖尿病学分会学术年会论文集,2011:128-129.
  • 4Roshandel D,Holliday KL,Pye SR,et al.Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men[J].Calcified Tissue International,2011,89(6):446-455.
  • 5Luo Y,Hu Z,Hao J,et al.Significant Associations Between the A163G and G1181C Polymorphisms of the Osteoprotegerin Gene and Risk of Osteoporosis,Especially in Postmenopausal Women:A Meta-Analysis[J].Genetic Testing and Molecular Biomarkers,2014,18(3):211-219.
  • 6Chao TH,Yu HN,Huang CC,et al.Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwan Residents women[J].Journal of the Chinese Medical Association,2012,75(7):335-340.
  • 7Zhang F,He C,Chen G,et al.Association analyses of osteoprotegerin gene polymorphisms withbone mineral density in Chinese postmenopausal women[J].Med Oncol,2013,30(1):389.
  • 8Shen L,Qiu Y,Xing S,et al.Association between osteoprotegerin genetic variants and bone mineral density in Chinese women[J].Int Immunopharmacol,2013,16(2):275-278.
  • 9Wang Q,Chen Z,Huang Y,et al.The relationship between osteoprotegerin gene polymorphisms and bone mineral density in Chinese postmenopausal women[J].Int Immunopharmacol,2013,17(2):404-407.
  • 10Takács I,Lazáryá,Kósa JP,et al.Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression[J].European Journal of Endocrinology,2010,162(2):423-431.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部